BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Eli Lilly and Company (LLY) Last Hope for Alzheimer's Drug as Johnson & Johnson (JNJ), Pfizer Inc. (PFE) Pull Out


8/8/2012 8:23:07 AM

For millions of people suffering from Alzheimer’s disease, an experimental drug from Eli Lilly & Co. (LLY) may now be their last hope for treatment. Pharmaceutical giants Pfizer Inc. (PFE) and Johnson & Johnson (JNJ) pulled the plug Aug. 6 on their joint development of a similar Alzheimer’s therapy, after that drug failed to show any benefit in two late-stage studies. Lilly has said it will release its findings by the end of September. The stakes are high both for the 5.4 million people in the U.S. who have been diagnosed with Alzheimer’s and for Lilly. There are no medicines on the market that slow the progression of the disease, the most common form of dementia. If Lilly’s drug proves a success, treatments could begin as early as next year and the Indianapolis-based company could realize billions of dollars in revenue. Still, company executives have warned that a successful outcome for the drug, solanezumab, is a long shot.

Read at Bloomberg

Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES